BRPI0413745A - horário mde dosagem para agentes anticancerìgenos erbb2 - Google Patents
horário mde dosagem para agentes anticancerìgenos erbb2Info
- Publication number
- BRPI0413745A BRPI0413745A BRPI0413745-0A BRPI0413745A BRPI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A
- Authority
- BR
- Brazil
- Prior art keywords
- erbb2
- mammal
- relates
- anticancer agents
- dosing schedule
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"HORáRIO DE DOSAGEM PARA AGENTES ANTICANCERìGENOS ERBB2". A presente invenção refere-se a métodos para um método para o tratamento da sobreexpressão do erbB2 em um mamífero com necessidade de tal tratamento através da administração ao mamífero de uma quantidade terapeuticamente eficaz de um primeiro inibidor de um receptor de erbB2 e depois, após um intervalo de menos do que 24 horas, administração ao mamífero dentre uma a seis quantidades terapeuticamente eficazes do O mesmo ou de um diferente inibidor do receptor de erbB2. A invenção também refere-se a uma infusão diária lenta do inibidor de erbB2. A sobreexpressão do receptor de erbB2 pode resultar em um crescimento celular anormal e levar ao câncer. Através dos métodos da invenção, a eficácia e segurança dos inibidores é melhorada. A invenção também refere-se a kits para facilitar o método de administração das dosagens da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49591903P | 2003-08-18 | 2003-08-18 | |
| PCT/IB2004/002580 WO2005016347A1 (en) | 2003-08-18 | 2004-08-06 | Dosing schedule for erbb2 anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0413745A true BRPI0413745A (pt) | 2006-10-24 |
Family
ID=34193358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0413745-0A BRPI0413745A (pt) | 2003-08-18 | 2004-08-06 | horário mde dosagem para agentes anticancerìgenos erbb2 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050119288A1 (pt) |
| EP (1) | EP1658080A1 (pt) |
| JP (1) | JP2007502807A (pt) |
| KR (2) | KR20080014144A (pt) |
| CN (1) | CN1838959A (pt) |
| AR (1) | AR045268A1 (pt) |
| AU (1) | AU2004264726A1 (pt) |
| BR (1) | BRPI0413745A (pt) |
| CA (1) | CA2536140A1 (pt) |
| CO (1) | CO5670356A2 (pt) |
| IL (1) | IL173127A0 (pt) |
| MX (1) | MXPA06001989A (pt) |
| NO (1) | NO20061252L (pt) |
| RU (1) | RU2328287C2 (pt) |
| SG (1) | SG135193A1 (pt) |
| TW (1) | TW200522966A (pt) |
| WO (1) | WO2005016347A1 (pt) |
| ZA (1) | ZA200600517B (pt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
| US8505468B2 (en) * | 2002-11-19 | 2013-08-13 | Sharp Kabushiki Kaisha | Substrate accommodating tray |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| CA2535614C (en) * | 2003-08-14 | 2009-12-22 | Array Biopharma Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| ES2279441T3 (es) | 2003-09-19 | 2007-08-16 | Astrazeneca Ab | Derivados de quinazolina. |
| CN1972688B (zh) | 2004-05-06 | 2012-06-27 | 沃尼尔·朗伯有限责任公司 | 4-苯胺基-喹唑啉-6-基-酰胺类化合物 |
| GB0427131D0 (en) * | 2004-12-10 | 2005-01-12 | Glaxosmithkline Biolog Sa | Novel combination |
| WO2006129163A1 (en) * | 2005-06-03 | 2006-12-07 | Pfizer Products Inc. | Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer |
| AU2006259261B2 (en) * | 2005-06-16 | 2013-06-13 | Myrexis, Inc. | Pharmaceutical compositions and use thereof |
| JP2009502960A (ja) * | 2005-07-27 | 2009-01-29 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 膵臓癌の処置のためのゲムシタビンおよびチロシンキナーゼ阻害剤を含む組み合わせ |
| US8945573B2 (en) * | 2005-09-08 | 2015-02-03 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Targeted identification of immunogenic peptides |
| CA2629714A1 (en) * | 2005-11-14 | 2007-05-24 | Ariad Gene Therapeutics, Inc. | Administration of an mtor inhibitor to treat patients with cancer |
| RU2592703C9 (ru) | 2005-11-15 | 2016-10-20 | Эррей Байофарма Инк. | ИНГИБИТОРЫ ТИПА ErbB |
| EP2010911A4 (en) * | 2006-03-31 | 2009-05-13 | Massachusetts Inst Technology | TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS |
| RU2008143554A (ru) * | 2006-04-05 | 2010-05-10 | Новартис АГ (CH) | Комбинации терапевтических агентов для лечения рака |
| AU2007319825B2 (en) | 2006-11-14 | 2014-01-23 | Ariad Pharmaceuticals, Inc. | Oral formulations |
| CA2720983A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating melanoma |
| WO2008124828A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating vascular disruption disorders |
| AU2008236993A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Method of treating brain cancer |
| AU2008236995A1 (en) * | 2007-04-10 | 2008-10-16 | Myrexis, Inc. | Dosages and methods for the treatment of cancer |
| WO2008124826A1 (en) * | 2007-04-10 | 2008-10-16 | Myriad Genetics, Inc. | Methods for treating cancer |
| WO2008154249A2 (en) * | 2007-06-08 | 2008-12-18 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| US8252805B2 (en) * | 2008-05-07 | 2012-08-28 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
| WO2010027848A2 (en) * | 2008-08-26 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib compounds and processes for the preparation thereof |
| KR20130080871A (ko) | 2009-03-20 | 2013-07-15 | 제넨테크, 인크. | 이중특이적 항-ｈｅｒ 항체 |
| CN104363914A (zh) | 2011-11-23 | 2015-02-18 | 因特利凯有限责任公司 | 使用mTOR抑制剂的增强的治疗方案 |
| JP6183471B2 (ja) | 2014-01-31 | 2017-08-23 | 凸版印刷株式会社 | 生体分子解析キット及び生体分子解析方法 |
| JP7057278B2 (ja) * | 2015-10-28 | 2022-04-19 | ターベダ セラピューティクス インコーポレイテッド | Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2001002192A0 (en) * | 2000-06-22 | 2002-12-21 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth. |
| HUP0402662A2 (hu) * | 2001-12-12 | 2005-05-30 | Pfizer Products Inc. | Az E-2-metoxi-N-(3-{4-[3-metil-4-(6-metilpiridin-3-iloxi)fenilamino]kinazolin-6-il}-allil)acetamid sói, előállításuk és rák elleni alkalmazásuk |
| MXPA04004107A (es) * | 2001-12-12 | 2004-07-23 | Pfizer Prod Inc | Moleculas pequenas para el tratamiento del crecimiento celular anormal. |
| EP1567506A4 (en) * | 2002-11-20 | 2007-06-20 | Array Biopharma Inc | CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR |
| CN1729001A (zh) * | 2002-12-18 | 2006-02-01 | 辉瑞产品公司 | 用于治疗异常细胞生长的4－苯胺基喹唑啉衍生物 |
-
2004
- 2004-08-06 JP JP2006523695A patent/JP2007502807A/ja not_active Withdrawn
- 2004-08-06 WO PCT/IB2004/002580 patent/WO2005016347A1/en active Application Filing
- 2004-08-06 BR BRPI0413745-0A patent/BRPI0413745A/pt not_active IP Right Cessation
- 2004-08-06 EP EP04744217A patent/EP1658080A1/en not_active Withdrawn
- 2004-08-06 KR KR1020087000092A patent/KR20080014144A/ko not_active Withdrawn
- 2004-08-06 CN CNA200480023705XA patent/CN1838959A/zh active Pending
- 2004-08-06 MX MXPA06001989A patent/MXPA06001989A/es not_active Application Discontinuation
- 2004-08-06 RU RU2006102125/14A patent/RU2328287C2/ru not_active IP Right Cessation
- 2004-08-06 KR KR1020067003190A patent/KR20060037447A/ko not_active Ceased
- 2004-08-06 SG SG200706063-5A patent/SG135193A1/en unknown
- 2004-08-06 AU AU2004264726A patent/AU2004264726A1/en not_active Abandoned
- 2004-08-06 CA CA002536140A patent/CA2536140A1/en not_active Abandoned
- 2004-08-17 US US10/919,831 patent/US20050119288A1/en not_active Abandoned
- 2004-08-17 AR ARP040102941A patent/AR045268A1/es not_active Application Discontinuation
- 2004-08-17 TW TW093124706A patent/TW200522966A/zh unknown
-
2006
- 2006-01-12 IL IL173127A patent/IL173127A0/en unknown
- 2006-01-18 ZA ZA200600517A patent/ZA200600517B/xx unknown
- 2006-02-15 CO CO06015089A patent/CO5670356A2/es not_active Application Discontinuation
- 2006-03-17 NO NO20061252A patent/NO20061252L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2536140A1 (en) | 2005-02-24 |
| TW200522966A (en) | 2005-07-16 |
| US20050119288A1 (en) | 2005-06-02 |
| JP2007502807A (ja) | 2007-02-15 |
| SG135193A1 (en) | 2007-09-28 |
| AU2004264726A1 (en) | 2005-02-24 |
| CO5670356A2 (es) | 2006-08-31 |
| AR045268A1 (es) | 2005-10-19 |
| KR20060037447A (ko) | 2006-05-03 |
| IL173127A0 (en) | 2006-06-11 |
| RU2006102125A (ru) | 2007-09-27 |
| MXPA06001989A (es) | 2006-05-17 |
| NO20061252L (no) | 2006-05-16 |
| RU2328287C2 (ru) | 2008-07-10 |
| CN1838959A (zh) | 2006-09-27 |
| EP1658080A1 (en) | 2006-05-24 |
| WO2005016347A1 (en) | 2005-02-24 |
| ZA200600517B (en) | 2007-02-28 |
| KR20080014144A (ko) | 2008-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0413745A (pt) | horário mde dosagem para agentes anticancerìgenos erbb2 | |
| DIONNE et al. | Suppression of postoperative pain by preoperative administration of ibuprofen in comparison to placebo, acetaminophen, and acetaminophen plus codeine | |
| Kosharskyy et al. | Intravenous infusions in chronic pain management | |
| BR0010524A (pt) | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico | |
| BR0110420A (pt) | Agonistas muscarìnicos | |
| BRPI0407375A (pt) | Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos | |
| TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
| Canavero et al. | Drug therapy of trigeminal neuralgia | |
| BRPI0413580A (pt) | composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp | |
| BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| IL128723A0 (en) | Pharmaceutical compositions containing rar antagonists and rxr agonists | |
| BRPI0607536A2 (pt) | tratamento de dor | |
| BR0014166A (pt) | Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual | |
| NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
| BRPI0517104A (pt) | tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico | |
| BR0316458A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto | |
| BR112022026247A2 (pt) | Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer | |
| BRPI0411608A (pt) | derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo | |
| JP2016507493A5 (pt) | ||
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| Jia et al. | CD73 regulates hepatic stellate cells activation and proliferation through Wnt/β-catenin signaling pathway | |
| Vallejo et al. | Preemptive analgesia with bupivacaine for segmental mastectomy | |
| Marri | Adjuvant agents in regional anaesthesia | |
| BRPI0417902A (pt) | piperazinas úteis no tratamento da dor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |